论文部分内容阅读
国家发改委近日公布2013年医药产业各项数据,表明2013年医药产业克服了欧美经济持续低迷等不利影响,产业主营业务收入、对外贸易总额、实现利润总额继续保持稳定增长,总体呈现平稳发展态势。2013年医药产业实现主营业务收入21 682亿元,同比增长17.9%。其中,化学药品原药3 820亿元,同比增长13.7%;化学药品制剂5 731亿元,同比增长15.8%;中药饮片1 259亿元,同比增长26.9%;中成药5 065亿元,同比增长21.1%;生物生化药品2 381亿元,同比增长17.5%;医疗器械1 889亿元,同比增长17.2%。
The National Development and Reform Commission recently released various data on the pharmaceutical industry in 2013, indicating that the pharmaceutical industry in 2013 had overcome the adverse effects of the sustained economic downturn in Europe and the United States. The revenue from major industries and the total volume of foreign trade continued to maintain steady growth with a steady increase in total profits, showing an overall stable development . In 2013, the revenue from main operations of the pharmaceutical industry reached 2.1682 trillion yuan, an increase of 17.9% over the same period of previous year. Among them, the original drug chemicals amounted to 382.0 billion yuan, up 13.7% over the same period of last year; chemical preparations amounted to 573.1 billion yuan, up 15.8% over the same period of last year; traditional Chinese medicine tablets amounted to 125.9 billion yuan, up 26.9% from the same period of last year; proprietary medicines amounted to 506.5 billion yuan, 21.1%; biochemical and biochemical drugs 2.381 trillion yuan, an increase of 17.5%; medical devices 1.889 trillion yuan, an increase of 17.2%.